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ABSTRACT
Increased expression and nuclear localization of Y-box-binding protein-1 (YB-1) are associated with drug resistance and
tumor progression. Detection of YB-1 primarily depends on the recognition of YB-1 antibody on its epitopes. To determine
the epitopes binding of anti-YB-1 A-16 and 59-Q antibodies, three YB-1 truncated proteins were generated using bacterial
expression system and their aberrant migration were reported. Epitope mapping analyses revealed anti-YB-1 A-16 antibody
recognized epitope at 1-127 amino acid residues of YB-1, whereas 59-Q antibody was reactive with epitope at 61-127 amino
acid residues. Based on our findings, 59-Q antibody was suggested used in the future study to avoid ambiguity.
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INTRODUCTION
The multifunctional human Y-box-binding
protein-1 (YB-1, P67809), also known as DNA
binding protein B (dbpB), belongs to evolutionary
conserved cold-shock domain (CSD) family which
is widely distributed among bacteria, plants and
animals (Wolffe et al., 1992). It plays role in a wide
range of cellular functions throughout the cell
development (Swamynathan et al., 2002, Fotovati
et al., 2011) and survival (Silveira et al., 2012, Lu
et al., 2005).
Several reports showed nuclear localization and
overexpression of YB-1 are associated with tumor
progression and drug resistance (Zhang et al., 2003,
Giménez-Bonafé et al., 2004). The multidrug-
resistant phenotype of cancers responds to
chemotherapy because of the multidrug transporter
P-glycoprotein. And this multidrug resistance 1
(MDR1) gene encoding P-glycoprotein is probable
transcriptionally regulated by YB-1 (Goldsmith et
al., 1993, Bargou et al., 1997, Ohga et al., 1998).
Thus, YB-1 is suggested as a novel molecular marker
of cancer progression and could be a useful target
in cancer treatment (Lasham et al., 2013).
A number of anti-YB-1 antibodies have been
raised to detect YB-1 protein, including
commercially available antibodies or in-house
produced antibodies. And these antibodies had been
applied to a wide range of human cancers, including
cancers of the prostate (Giménez-Bonafé et al.,
2004), lung (Shibahara et al., 2001), skin (Schittek
et al., 2007), bone (Oda et al., 1998), and others
(Chatterjee et al., 2008, Ito et al., 2003, Oda et al.,
2003). However, there are evident that different anti-
YB-1 antibodies show different immunoreactivity
property and are ascribed to the epitopes
accessibility and YB-1 protein complexes (Woolley
et al., 2011). Therefore, Cohen et al. (2010) warrant
re-assessment in some cases about the association
of detection of nuclear YB-1 and tumor progression.
The purpose of this work was to map the linear
epitopes recognized by commercially available anti-
YB-1 antibodies by using truncated proteins. Before
this, it is necessary to construct, optimize and purify
the production of YB-1 truncated proteins using
bacterial expression system. Here, we generated two
non-overlapping truncated proteins: N-terminal (N),
cold-shock domain (CSD) and one overlapping
truncated proteins (N+CSD) for epitope mapping,
thus identifying a range of epitopes necessary
recognized by anti-YB-1 polyclonal (A-16) and
monoclonal (59-Q) antibodies.
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MATERIALS AND METHODS
Construction of truncated genes
The N, CSD and N+CSD gene were amplified
from pCR-®2.1-YB-1 plasmid which carries full-
length of human YB-1 gene (1-324 aa), by standard
polymerase chain reaction (PCR) using recombinant
pfu DNA polymerase (Fermentas, USA) with the
primers containing NdeI and AgeI cleavage sites.
Annealing temperature for each gene was optimized
through a gradient PCR. The amplified DNA
fragments were purified using QIAquick PCR
purification kit (QIAGEN, Germany), and
subsequently cloned into pCR®2.1-TOPO® vector
(Invitrogen, USA) after adding with 3’A-overhangs
using Taq polymerase (Fermentas, USA). E. coli
strain TOP10 cells was chemically transformed with
the plasmids and selected on LB agar plates
containing 50 μg/mL kanamycin and 40 mg/mL X-
gal. Plasmid DNA of selected cells was purified with
QIAprep Miniprep kits (QIAGEN, Germany), then
confirmed by restriction analysis using NdeI and
AgeI enzymes and verified by M13 forward and
reverse DNA sequencing. Then, all DNA fragments
in the plasmids were excised at NdeI and AgeI sites
and gel purified using QIAquick Gel Extraction kit
(QIAGEN, Germany). The purified DNA fragments
were ligated to linearized pET16b(SH3) expression
vector (Novagen, USA) using T4 DNA Ligase
(Fermentas, USA). E. coli strain BL21 (DE3) cells
were chemically transformed with the plasmids and
selected on LB agar plates containing 100 μg/mL
ampicillin. Selected cells harboring the plasmid
DNA were purified using QIAprep Miniprep kit
(QIAGEN, Germany), then confirmed by restriction
analysis using NdeI and AgeI enzymes and verified
by T7 promoter and terminator DNA sequencing.
Protein Expression and Optimization
E. coli strain BL21 (DE3) cells harboring
plasmids were streaked on LB agar plates
supplemented 100 μg/mL ampicillin and cultured
for overnight at 37ºC. A single colony of bacteria
was inoculated into 10 mL LB broth and incubated
agitating overnight at 37ºC. The LB medium
(10 mL) was added with 100 μL overnight bacterial
culture and incubated agitating at 37ºC. At an
OD600 of ≈ 0.5, 1 mM of IPTG at final concentration
was added to induce the protein expression, and
then continued incubated agitating and collected
at 0 hour, 0.5 hour, 1 hour, 2 hours and 3 hours,
respectively. The harvested cells were washed three
times with ice-cold PBS (2.7 mM KCl, 137 mM
NaCl, pH 7.4) and lysed in urea lysis buffer (7 M
urea, 20 mM HEPES, pH 7) added with 3 Unit/mL
Benzonase® Nuclease (Merck, Germany). The cells
were frozen at -80ºC overnight and vortex
vigorously. Supernatant was collected after
centrifugation at 9,000 x g for 30 minutes at 4ºC.
SDS-PAGE and Western blotting
Sample proteins were resolved on reducing 12%
(w/v) SDS-PAGE and then visualized after
coomassie brilliant blue staining. For Western
blotting, the gel was transferred to Immobilon P
polyvinylidene difluoride filter (Millipore, USA) by
semi-dry electroblotting (Biorad, USA) 12 V for 1 h
room temperature. The membrane was then blocked
with blocking buffer [1x TBS, 5% (w/v) skimmed
milk, 0.1% (v/v) Tween 20] for 90 minutes at room
temperature under agitating. The membrane was
washed three times with washing buffer [0.5% (v/v)
Tween 20, 1 x TBS], each for 10 minutes at room
temperature. The membrane was then probed with
primary antibody at 4ºC for overnight and washed
again three times with washing buffer. Then, the
membrane was probed with a horseradish peroxidase-
linked secondary antibody under agitating at room
temperature for 1 hour, followed by three times
washing.  Image was developed using ECL solution
(Millipore, USA) and exposed to Hyperfilm
(Amersham, UK) varied for 1-10 minutes, processed
using Fuji medical film processor (Fuji, Japan).
Protein purification
A total amount of 6 mL bacterial cleared cell
lysate was loaded on 1 mL bed volume of pre-
equilibrated nickel-nitrilotriacetic acid agarose
(QIAGEN, Germany) and flow through was collected.
The column was then washed with 10 mL wash
buffer (130 mM imidazaole, 8 M urea, 100 mM
NaH2PO4, 100 mM Tris-Cl, 300 mM NaCl, pH 8) and
wash fraction was collected. Purified protein was
eluted 4 times with 500 μL of elution buffer (500
mM imidazole, 8 M urea, 100 mM NaH2PO4, 100
mM Tris-Cl, 300 mM NaCl, pH 8) and all fractions
were collected.
Antibodies
YB-1 antibodies goat polyclonal (A-16): sc-
18057, mouse monoclonal antibody (59-Q): sc-
101198, goat anti-mouse antibody sc-2005 and
rabbit anti-goat antibody sc-2768 were supplied
from Santa Cruz Biotechnology, U.S.A. Anti-6x His
tag ® (ab18184) mouse monoclonal antibody
[His.H8] was supplied from Abcam, U.S.A.
Cell line
HeLa cells were cultured in DMEM/F12-medium
(Invitrogen, U.S.A) containing 10% (v/v) fetal
bovine serum (Invitrogen, U.S.A) and harvested after
reaching confluent. The harvested cells were
subsequently subjected to lysis in RIPA buffer (50
mM TrisCl pH 7.4, 150 mM NaCl, 1% NP40, 0.5%
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Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM
EDTA and 50 mM NaF) and incubated overnight at
4ºC. Supernatant was collected after the lysate was
centrifuged at 5,000 x g for 30 minutes at 4ºC.
Expression vector
The pET16b(SH3) expression vector, used in
this study is shown in figure 2. This modified vector
is based on the pET16b expression vector (Novagen,
USA) containing 10x histidine residues and added
four cysteine residues between AgeI and XhoI
cleavage sites, which enable protein-protein
interaction study in future.
Protein molecular weight determination
Theoretical molecular weight of proteins was
computed using Compute pI/Mw tool from ExPASy
(available at: http://web.expasy.org/compute_pi/).
The apparent migration size of proteins on 12%
(w/v) SDS-PAGE gel was estimated and referred to
the pre-stained protein ladder (Fermentas, USA).
RESULTS
Amplification and construction of YB-1 genes
Amplification of YB-1 genes (Figure 1) was
performed using the designed primers and the
optimized parameters listed in Table 1. Our
unpublished data demonstrated amplification of
YB-1 genes using these parameters produced good
specific target bands by PCR. YB-1 truncated genes
were cloned into the modified pET16b(SH3) vectors
(Figure 2) and these constructs expressed 10x
histidine tag recombinant proteins and following
tailed by 4 x cysteine amino acid residues. Figure 3
showed the His-tagged YB-1 truncated proteins were
resolved on 12% (w/v) gel and the membrane by
anti-His tag antibody at 1:1000 dilution.
Optimizing expression of YB-1 truncated proteins
Expression of YB-1 truncated proteins in E. coli
strain BL21(DE3) were optimized through small-
scale time-course induction study under induction
Table 1. Primers for amplification of YB-1 truncated gene. NdeI and AgeI excision sites are indicated in boldface
letters for forward primers and reverse primers, respectively
Truncated genes
        Forward primers         Reversed primers Optimized annealing
        (sizes) temperature (°C)
N (180 bp) 5’-ATG CAT ATG 5’-TCA CCG GTT 55.4
AGC AGC GAG GCC GAG -3’ TCC CAA AAC CTT CGT TG-3’
CSD (201 bp) 5’-CGG CAT ATG 5’-TCA CCG GTG 48.0–52.0
GGA ACA GTA AAA TGG-3’ ACC TGT AAC ATT TG -3’
N+CSD (381 bp) 5’-ATG CAT ATG 5’-TCA CCG GTG 50.2
AGC AGC GAG GCC -3’ ACC TGT AAC ATT TG -3’
Fig. 1. Schematic illustration of YB-1 full-length protein and truncated proteins. (a): Primary structure
of YB-1 polypeptide: alanine-proline (A/P) rich N-terminal domain, a central CSD and a tailed C-
terminal domain (CTD). CTD consists of a nuclear localization signal (NLS), a cytoplasmic retention
signal (CRS) and a 20S Proteasome cleavage site. (b): The 10x histidine-tagged YB-1 truncated proteins
and tailed by 4x cysteines.
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Table 2. Time-course induction study in E. coli strain BL21
(DE3). Expression of YB-1 truncated proteins was induced
by 1 mM IPTG at final concentration and harvested at 0,
30 min, 1 hour, 2 hours and 3 hours. Cleared cell lysates
containing the truncated proteins were resolved on 12%
(w/v) gel and probed by Western blot
Truncated proteins N CSD N+CSD
Optimal induction 30 m, 37°C 1 h, 37°C 2 h, 37°C
condition
Fig. 2. Plasmid map of modified pET16b(SH3) expression
vector (gift of Elena Klenova). It contains the placement of
four cysteine amino acid residues at AgeI and XhoI cleavage
sites. Digested DNA fragment at NdeI and AgeI cleavage
sites can be cloned into pET16(SH3) vector.
Fig. 3. Expression of His-tagged YB-1 truncated proteins:
N, CSD and N+CSD. Cleared cell lysates of expressed
proteins were resolved on 12% (w/v) SDS-PAGE and
probed by anti-His tag monoclonal antibody on Western
blot at 1:1000 dilution. An arrow indicates the authentic
protein size. Induction condition of expressed proteins is
denoted: uninduced (-) and induced (-).
of 1 mM IPTG at 37ºC. Visual inspection of the
apparent thickest band on Western blot probed by
anti-His tag antibody was justified as a maximal
protein yield. As shown in Table 2, high level
expression of truncated proteins was obtained under
precise induction timing and temperature.
Optimization and purification of YB-1 truncated
proteins
Purification of YB-1 truncated proteins was
initially performed through stepwise protein elution
study using Ni-NTA spin column (QIAGEN,
Germany). Our internal data demonstrated 10x
histidine tagged recombinant proteins were starting
eluted at 150 mM of imidazole. Thus, YB-1
truncated proteins were washed with 130 mM
imidazole and all purified proteins were eluted at
500 mM imidazole buffer. Figure 4-6 showed a
single purified protein band were resolved on 12%
(w/v) SDS-PAGE.
Anomalous migration of YB-1 truncated proteins
Migration of denatured YB-1 truncated proteins
was analyzed on reducing 12% (w/v) SDS-PAGE
and probed by Western blot using anti-His tag
antibody (Figure 3). The migration size of YB-1
proteins was compared to their theoretical molecular
weight and percentage of aberrant migration
calculated in Table 3. The percentage of aberrant
migration of protein was calculated as following:
SDS-PAGE (kDa) – Theoretical (kDa)
% of Aberrant Migration =  x 100%
Theoretical (kDa)
Validation of anti-His tag antibody and YB-1
antibodies
Prior to Western blot study of YB-1 truncated
proteins, anti-His tag mouse monoclonal antibody
was validate at 1:1000 dilution, which specifically
detected the 70-kDa 10x Histidines tagged zinc
fingers of transcriptional repressor CTCF protein
(Chernukhin et al., 2000) and was non-reactive to
cleared cell lysates of E. coli BL21 (DE3) without
harboring a plasmid by Western blot (Figure 7a).
Anti-YB-1 goat polyclonal (A-16) (sc-18057, Santa
Cruz) antibody and mouse monoclonal (59-1)
(sc-101198, Santa Cruz) antibody were validated at
1:1000 dilution and specifically detected 49-kDa
YB-1 protein in HeLa cell cleared lysate by Western
blot (Figure 7b).
Epitope mapping of anti-YB-1 antibodies
Using three purified YB-1 truncated proteins: N,
CSD and N+CSD, anti-YB-1 goat polyclonal (A-16)
antibody and mouse monoclonal (59Q) antibody
were probed on these proteins by Western blot at
their validated dilution. Figure 8 demonstrated the
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Table 3. The molecular weight determination of YB-1 truncated proteins. Theoretical molecular weight of YB-1 proteins
were calculated from ExPASy Compute pI/Mw tool and compared to the apparent migration on 12% (w/v) SDS-PAGE.
Their discrepancies in migration are shown in percentage
Truncated Number of Theoretical
                          Molecular weight/ kDa Aberrant
protein amino acids (aa) pI† migrationTheoretical† Migration size on 12% (w/v) (%)SDS-PAGE (Reducing)
N 60 4.94 5.46 14 156.41
CSD 67 5.72 7.81 14 79.26
N+CSD 127 5.82 12.91 22 70.41
†Calculation excluding endogenous pET16b (SH3) vector encoding of 3.18 kDa of 10 x histidine tag and 4 x cysteine tag
Fig. 5. The purification of CSD protein was analyzed on 12% (w/v) SDS-PAGE.
Lane M: Pre-stained protein ladder; Lane 1: Flow-through fraction; Lane 2: Wash
fraction with 130 imidazole buffer; Lane 3-6: Eluted fractions with 500 mM imidazole
buffer. Arrow indicates the obtained purified CSD protein.
Fig. 4. The purification of N protein was analyzed on 12% (w/v) SDS-PAGE. Lane
M: Pre-stained protein ladder; Lane 1: Flow-through fraction; Lane 2: Wash fraction
with 130 imidazole buffer; Lane 3-6: Eluted fractions with 500 mM imidazole buffer.
Arrow indicates the obtained purified CSD protein.
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Fig. 6. The purification of N+CSD protein was analyzed on 12% (w/v) SDS-
PAGE. Lane M: Pre-stained protein ladder; Lane 1: Flow-through fraction; Lane
2: Wash fraction with 130 imidazole buffer; Lane 3-6: Eluted fractions with 500
mM imidazole buffer. Arrow indicates the obtained purified CSD protein.
Fig. 7. Validation of anti-YB-1 antibodies and anti-His tag
antibody. (a) Anti-YB-1 polyclonal antibody (59-Q) and
monoclonal antibody (A-16) detected YB-1 protein in HeLa
cleared cell lysate in 1:1000 dilution. (b) Anti-His tag
monoclonal antibody detected zinc fingers of CTCF protein
and not reactive with cleared cell lysates of non-harboring
plasmid E. coli strain BL21 (DE3) in 1:1000 dilution.
Fig. 8. Western blot of anti-YB-1 (59-Q) monoclonal
antibody on YB-1 truncated proteins. These purified
truncated proteins were resolved on 12% (w/v) gel and
probed by Western blot at 1:1000 dilution of antibody. An
arrow indicates the detected protein.
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Table 4. Summary of epitope mapping of YB-1 antibodies
Immunoreactivity
Anti-YB-1
N CSD N+CSDantibodies
(1-60 aa) (61-127 aa) (1-127 aa)
A-16 polyclonal – – +
antibody
59-Q monoclonal – + +
antibody
aa: amino acid residues; (–): not reactive; (+): reactive
Fig. 9. Western blot of anti-YB-1 (A-16) polyclonal
antibody on YB-1 truncated proteins. These purified
truncated proteins were resolved on 12% (w/v) gel and
probed by Western blot at 1:1000 dilution of antibody. An
arrow indicates the detected protein.
bands were detected on CSD protein and N+CSD
protein probed by anti-YB-1 (59-Q) mouse
monoclonal antibody at 1:1000 dilution. In contrast,
Figure 9 indicated only a single band was detected
on N+CSD protein probed by anti-YB-1 (A-16) goat
polyclonal antibody at 1:1000 dilution. Table 4
summarized the epitope mapping of these anti-
YB-1 antibodies.
DISCUSSION
In this study we have shown that the constructed
truncated proteins from YB-1 gene were successfully
expressed in E. coli strain BL21 (DE3). In addition,
these proteins were optimized their expression
through the time-course induction study under 1
mM IPTG induction and successfully purified them
using immobilized metal affinity chromatography in
order to remove bacterial contaminant proteins. In
general, YB-1 consists of 324 amino acid residues,
the predominating one being Arginine (11.7%),
Glycine (12%), Proline (11%), and Glutamine (8.35)
(Eliseeva et al., 2011). YB-1 is comprised of three
main domains: N-terminal domain (N), Cold-shock
domain (CSD) and C-terminal domain (C) (Wolffe,
1994). Here, the denatured YB-1 truncated proteins:
N, CSD and N+CSD aberrantly migration on 12%
(w/v) reducing gels, despite of their calculated
molecular weight. Among these proteins, N protein
showed the highest percentage in peculiarity of
migration. These aberrant migrations can be as a
result of several factors (Rath et al., 2009, Armstrong
and Roman, 1993, Manning and Colon, 2004). Here,
we speculated N and CSD proteins contributed to
anomalous migration of full-length YB-1. However,
the protein sequencing of proteins needs to be
carried out in order to confirm these results.
Anomalous migration of YB-1 is known to
migrate as a 45-50 kDa protein on SDS-PAGE gels;
however its molecular weight calculated by the
amino acid sequence is about 35.9 kDa. And this
discrepancy is suggested due to anomalous
electrophoretic mobility (Skabkin et al., 2004). Our
results showed using anti-YB-1 (A-16) polyclonal
and (59-Q) monoclonal antibodies, migration size
of YB-1 protein in HeLa cell lysates on 12% (w/v)
reducing gels was identical with the detection of
purified p50 (YB-1) from reticulocytes (Evdokimova
et al., 1995). In addition, these two antibodies
detected no so-called smaller protein band, which
was previously presumed as cleavage of a short
C-terminal YB-1 fragment by 20S Proteasome
(Sorokin et al., 2005) but was then revealed as
hnRNPA1 instead (Cohen et al., 2010).
Epitope mapping is the process of identification
of the binding sites or epitopes of antibody. A
number of methods have been developed for
mapping protein epitopes of antibodies (Ladner,
2007). A popular strategy involves probing the
antibody-binding ability of synthetic peptides
derived from the amino acid sequence of the
antigen (Baerga-Ortiz et al., 2002). In contrast,
epitope mapping of anti-YB-1 antibodies employed
in this study was using YB-1 truncated proteins
(linear epitopes) instead of synthetic peptides and
it would be able roughly locating the binding sites
of antibodies. In fact, this technique had been
applied in several epitope mapping studies (Wade-
Evans and Jenkins, 1985, Raux et al., 1997,
Meysick et al., 2001).
Our data presented anti-YB-1 (A-16) polyclonal
antibody recognized YB-1 protein containing
epitopes located between 1-127 amino acid residues.
Indirectly, this data also implied that N or CSD
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protein individually abolished the recognition by
anti-YB-1 (A-16) antibody. This 127-amino-acid
region belongs to N and CSD domains of YB-1. The
N-terminal sequence of YB-1, containing the
alanine-proline rich domain, involves in regulating
the progression of cells from G2/M to G1 phase in
a cell cycle (Khandelwal et al., 2009). While the
CSD is an oligosaccharide-/oligonucleotide-binding
(OB fold), which comprises of a five-stranded β-
barrel that includes two RNA-binding sequence
motifs RNP1 and RNP2 (Kloks et al., 2002), and
shares functional properties with the major proteins
of heterogeneous nuclear RNPs (hnRNPs). Although
there is no apparent similarity in amino acid
sequences between YB-1 and hnRNPs, but the
molecular mimicry between them leads to the cross-
reactivity of anti-YB-1 antibody, which recognized
the epitope at 23-52 amino acid residues (Cohen et
al., 2010). Coincidently, the epitope of anti-YB-1
(A-16) antibody were revealed located at 25-75
amino acid residues (Santa Cruz, personal
communication). According to its product datasheet
(sc-18057, Santa Cruz), anti-YB-1 (A-16) antibody
specifically detected about 37-kDa protein band in
several cell lines by Western blot, but we detected
at 49 kDa in HeLa cells. In Cohen et al. (2010)
study, the 37-kDa protein band proposed as activated
YB-1 was eventually identified as as hnRNP A1.
Thus, it was speculated used of this antibody would
probable render the cross-reaction problem and
misidentification of YB-1 in several cited studies
(Perez-Leal et al., 2012, Sano et al., 2008, Chibi et
al., 2008, Homer et al., 2005, Kojic et al., 2004).
On the other hand, anti-YB-1 (59-Q)
monoclonal antibody was shown specifically
reactive with YB-1 truncated protein containing
epitope 61-127 amino acid residues. Therefore, CSD
or N+CSD protein containing this epitope region
was detected in Western blot except for N protein.
In light of this epitope, anti-YB-1 (59-Q) antibody
was disclosure against the epitope at 51-140 amino
acid residues of YB-1 (Santa Cruz, personal
communication), which was approximately identical
to our data.  Thus, this antibody is recommended
to probe the YB-1 protein in future with
disambiguation. Taken together these data, it was
important to avoid the used of cross-reactivity
epitope of amino acid sequence in production of
antibody.
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